CARA · Cara Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $2.57M | - | $2.56M | $991.0K | $2.13M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.91M | - | $3.60M | $5.81M | $319.0K | - | $1.36M | $9.31M | $21.96M | - |
| SG&A | $2.14M | - | $2.33M | $3.06M | $4.64M | - | $6.47M | $6.41M | $6.82M | - |
| Total Operating Expenses | $7.05M | - | $5.94M | $8.87M | $4.96M | - | $8.54M | $18.30M | $31.80M | - |
| D&A | $24.0K | - | - | - | $0 | - | - | - | $42.0K | - |
| Operating Income | ($7.05M) | - | ($5.94M) | ($8.87M) | ($2.39M) | - | ($5.99M) | ($17.31M) | ($29.67M) | - |
| Interest Expense | $558.0K | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($6.80M) | - | ($5.53M) | $4.17M | ($4.91M) | - | ($12.48M) | ($20.02M) | ($30.70M) | - |
| EPS - Basic | ($0.73) | - | ($0.59) | $0.51 | ($3.22) | - | ($0.23) | ($0.37) | ($0.56) | - |
| EPS - Diluted | ($0.73) | - | ($0.59) | ($1.00) | ($3.22) | - | ($0.23) | ($0.37) | ($0.56) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.85M | $20.73M | $21.42M | $20.65M | $34.22M | $37.90M | $37.06M | $49.24M | $47.00M | $51.77M |
| Accounts Receivable | - | - | - | - | $1.23M | $407.0K | $435.0K | $359.0K | $1.72M | $2.77M |
| Inventory | - | - | - | - | $900.0K | $900.0K | $625.0K | $1.64M | $2.74M | $2.82M |
| Accounts Payable | $4.62M | $3.22M | $4.08M | $2.42M | $4.0K | $1.43M | $2.54M | $6.75M | $4.98M | $11.58M |
| Current Assets | $25.33M | $31.54M | $38.44M | $43.13M | - | $43.83M | $47.91M | $63.86M | $81.22M | $116.16M |
| Total Assets | $25.82M | $32.07M | $39.02M | $43.75M | $38.95M | $43.83M | $51.33M | $72.50M | $90.10M | $125.84M |
| Current Liabilities | $11.26M | $11.04M | $11.04M | $10.68M | $1.20M | $3.97M | $10.04M | $13.90M | $15.10M | $25.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $11.31M | $11.13M | $11.15M | $10.82M | $47.02M | $48.42M | $50.62M | $60.90M | $60.30M | $68.76M |
| Stockholders' Equity | $14.51M | $20.95M | $27.87M | $32.93M | ($8.07M) | ($4.59M) | $707.0K | $11.60M | $29.80M | $57.09M |
| Retained Earnings | ($117.25M) | ($110.45M) | ($103.17M) | ($97.65M) | ($760.52M) | ($755.61M) | ($747.93M) | ($735.46M) | ($715.44M) | ($684.75M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.86M) | - | - | - | ($4.69M) | - | - | - | ($30.45M) | - |
| Investing Cash Flow | $4.98M | - | - | - | - | - | - | - | $25.95M | - |
| Financing Cash Flow | - | - | - | - | $1.01M | - | - | - | ($685.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | $836.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($31.29M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -92.9% | - | -234.3% | -1746.3% | -1389.5% | - |
| EBITDA margin | - | - | - | - | -92.9% | - | - | - | -1387.5% | - |
| Net margin | - | - | - | - | -191.0% | - | -488.1% | -2019.8% | -1437.8% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -1465.5% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.02 | - |
| R&D / Revenue | - | - | - | - | 12.4% | - | 53.3% | 939.3% | 1028.8% | - |
| SG&A / Revenue | - | - | - | - | 180.5% | - | 253.3% | 646.6% | 319.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.4% | - | -14.2% | 9.5% | -12.6% | - | -24.3% | -27.6% | -34.1% | - |
| Return on equity | -46.9% | - | -19.8% | 12.7% | 60.8% | - | -1764.6% | -172.6% | -103.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.25 | 2.86 | 3.48 | 4.04 | - | 11.03 | 4.77 | 4.59 | 5.38 | 4.54 |
| Quick ratio | 2.25 | 2.86 | 3.48 | 4.04 | - | 10.81 | 4.71 | 4.48 | 5.20 | 4.43 |
| Cash ratio | 1.76 | 1.88 | 1.94 | 1.93 | 28.54 | 9.54 | 3.69 | 3.54 | 3.11 | 2.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -12.6x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.78 | 1.53 | 1.40 | 1.33 | -4.82 | -9.54 | 72.60 | 6.25 | 3.02 | 2.20 |
| Liabilities / Assets | 0.44 | 0.35 | 0.29 | 0.25 | 1.21 | 1.10 | 0.99 | 0.84 | 0.67 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | 0.07 | - | 0.05 | 0.01 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 175d | - | 62d | 132d | 294d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | 20.3% | - | -47.5% | -85.7% | -65.4% | - |
| Revenue CAGR (3y) | - | - | - | - | -18.8% | - | -49.9% | - | 3.3% | - |
| Revenue CAGR (5y) | - | - | - | - | -20.5% | - | -15.1% | -28.2% | -13.4% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -195.5% | - | 0.8% | 48.8% | 92.0% | - | 79.3% | 46.5% | -7.3% | - |
| Net income growth (YoY) | -38.7% | - | 55.7% | - | 84.0% | - | 55.5% | 36.4% | -15.1% | - |
| EPS growth (YoY) | 77.3% | - | -156.5% | -170.3% | -475.0% | - | 55.8% | 36.2% | -14.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | 3841.4% | 183.9% | - | - | -99.2% | -89.4% | -78.2% | -64.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$10.76M totalOther Revenue$4.33M · 40.2%
Collaborative Revenue$2.09M · 19.4%
Other Non Cash Revenue$1.49M · 13.9%
Other Revenue Non Cash$1.49M · 13.9%
Commercial Supply Revenue$640.0K · 5.9%
Commercial Supply Revenue With Associated Costs Of Goods Sold$640.0K · 5.9%
Clinical Compound Revenue$84.0K · 0.8%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cara Therapeutics against the 5 most active filers in the same SIC group.